COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
1 . A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis comprising administering to the subject an amount of a biologically active agent effective to treat the condition, wherein the agent is a compound of the formula:
wherein
R 1 is hydrogen or alkyl having from 1 to 7 carbon atoms;
or when R 1 is hydrogen, a pharmaceutically acceptable salt of the compound.
2 . The method of claim 1 , wherein the agent is administered orally.
3 . The method of claim 1 , wherein the subject is a human.
4 . The method of claim 3 , wherein the agent is administered in an amount from one milligram to four hundred milligrams per day.
5 . The method of claim 1 , wherein the condition is insulin resistance syndrome or Type II Diabetes.
6 . The method of claim 1 , wherein the condition is Type 1 Diabetes.
7 . The method of claim 1 , wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.
8 . The method of claim 1 , wherein R 1 is hydrogen or ethyl.
9 . The method of claim 8 , wherein the compound is 4-(2,6-difluorophenyl)-4-oxobutyric acid.